메뉴 건너뛰기




Volumn 29, Issue 33, 2011, Pages 4345-4346

Determining the best dose for the individual patient

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYLIC ACID; DOCETAXEL; LACTONE; TOPOTECAN;

EID: 81755172061     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2572     Document Type: Editorial
Times cited : (5)

References (18)
  • 1
    • 0036279836 scopus 로고    scopus 로고
    • Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan
    • DOI 10.2174/1568009023333890
    • Mathijssen RH, Loos WJ, Verweij J, et al.: Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2:103-123, 2002 (Pubitemid 34625479)
    • (2002) Current Cancer Drug Targets , vol.2 , Issue.2 , pp. 103-123
    • Mathijssen, R.H.J.1    Loos, W.J.2    Verweij, J.3    Sparreboom, A.4
  • 2
    • 0028937909 scopus 로고
    • The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs
    • Burke TG, Munshi CB, Mi Z, et al.: The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84:518-519, 1995
    • (1995) J Pharm Sci , vol.84 , pp. 518-519
    • Burke, T.G.1    Munshi, C.B.2    Mi, Z.3
  • 3
    • 81755171117 scopus 로고    scopus 로고
    • Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study
    • Park JR, Scott JR, Stewart CF, et al.: Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. J Clin Oncol 29:4351-4357, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 4351-4357
    • Park, J.R.1    Scott, J.R.2    Stewart, C.F.3
  • 6
    • 79851510815 scopus 로고    scopus 로고
    • Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma
    • De Ioris MA, Castellano A, Ilari I, et al.: Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. Eur J Cancer 47:572-578, 2011
    • (2011) Eur J Cancer , vol.47 , pp. 572-578
    • De Ioris, M.A.1    Castellano, A.2    Ilari, I.3
  • 7
    • 77956245879 scopus 로고    scopus 로고
    • Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study
    • London WB, Frantz CN, Campbell LA, et al.: Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 28:3808-3815, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 3808-3815
    • London, W.B.1    Frantz, C.N.2    Campbell, L.A.3
  • 8
    • 0033927215 scopus 로고    scopus 로고
    • Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens
    • Loos WJ, Gelderblom H, Sparreboom A, et al.: Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens. Clin Cancer Res 6:2685-2689, 2000 (Pubitemid 30482104)
    • (2000) Clinical Cancer Research , vol.6 , Issue.7 , pp. 2685-2689
    • Loos, W.J.1    Gelderblom, H.2    Sparreboom, A.3    Verweij, J.4    De Jonge, M.J.A.5
  • 10
    • 79251496487 scopus 로고    scopus 로고
    • Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study
    • Engels FK, Loos WJ, van der Bol JM, et al.: Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study. Clin Cancer Res 17:353-362, 2011
    • (2011) Clin Cancer Res , vol.17 , pp. 353-362
    • Engels, F.K.1    Loos, W.J.2    Van Der Bol, J.M.3
  • 12
    • 34848904408 scopus 로고    scopus 로고
    • The relevance of microdialysis for clinical oncology
    • Kitzen JJ, Verweij J, Wiemer EA, et al.: The relevance of microdialysis for clinical oncology. Curr Clin Pharmacol 1:255-263, 2006
    • (2006) Curr Clin Pharmacol , vol.1 , pp. 255-263
    • Kitzen, J.J.1    Verweij, J.2    Wiemer, E.A.3
  • 14
    • 30544438066 scopus 로고    scopus 로고
    • Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment
    • DOI 10.1016/j.ejca.2005.08.035, PII S0959804905009299
    • Mathijssen RH, van Schaik RH: Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment. Eur J Cancer 42:141-148, 2006 (Pubitemid 43083482)
    • (2006) European Journal of Cancer , vol.42 , Issue.2 , pp. 141-148
    • Mathijssen, R.H.J.1    Van Schaik, R.H.N.2
  • 16
    • 80052009180 scopus 로고    scopus 로고
    • Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
    • de Graan AJ, Teunissen SF, de Vos FY, et al.: Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 29:3240-3246, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 3240-3246
    • De Graan, A.J.1    Teunissen, S.F.2    De Vos, F.Y.3
  • 17
    • 0029743058 scopus 로고    scopus 로고
    • Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
    • Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 2590-2611
    • Gurney, H.1
  • 18
    • 78049256742 scopus 로고    scopus 로고
    • Dose-escalation models for combination phase I trials in oncology
    • Hamberg P, Ratain MJ, Lesaffre E, et al.: Dose-escalation models for combination phase I trials in oncology. Eur J Cancer 46:2870-2878, 2010
    • (2010) Eur J Cancer , vol.46 , pp. 2870-2878
    • Hamberg, P.1    Ratain, M.J.2    Lesaffre, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.